1-(1H-Benzoimidazol-2-yl)-2,2-dimethyl-propan-1-one | 76098-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(1H-Benzoimidazol-2-yl)-2,2-dimethyl-propan-1-one
• 英文别名: 1-(1H-benzimidazol-2-yl)-2,2-dimethylpropan-1-one
• CAS: 76098-80-1
• 化学式: C₁₂H₁₄N₂O
• 分子量: 202.256
• InChiKey: QUZVQJZMBJHCDZ-UHFFFAOYSA-N

物化性质

• 沸点：
  356.1±25.0 °C(Predicted)
• 密度：
  1.147±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(1H-Benzoimidazol-2-yl)-2,2-dimethyl-propan-1-one 、 alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydride 作用下， 生成 C₁₅H₁₈N₂O₂
  参考文献：
  名称：

  Dostert; Langlois; Guerret, European Journal of Medicinal Chemistry, 1980, vol. 15, # 3, p. 199 - 205

  摘要：

  DOI：
• 作为产物：
  描述：

  2-羟基-3,3-二甲基丁酸 在 manganese(IV) oxide 作用下， 生成 1-(1H-Benzoimidazol-2-yl)-2,2-dimethyl-propan-1-one
  参考文献：
  名称：

  Dostert; Langlois; Guerret, European Journal of Medicinal Chemistry, 1980, vol. 15, # 3, p. 199 - 205

  摘要：

  DOI：

文献信息

• Indole and Benzimidazole Derivatives
  申请人：Boyce Rustum S.

  公开号：US20080317744A1

  公开（公告）日：2008-12-25

  The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:

  本发明涉及新的吲哚和苯并咪唑化合物及其药学上可接受的盐、酯或前药，新化合物与药学上可接受的载体的组合物，以及新化合物的用途。本发明的化合物具有以下一般式：
• L-ALANINE DERIVATIVES
  申请人：Kettle Grant Jason

  公开号：US20090111828A1

  公开（公告）日：2009-04-30

  The present invention relates to compounds that inhibit of a5 b 1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5 b 1 and also that exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及抑制a5b1功能的化合物，其制备过程，含有其作为活性成分的制药组合物，以及它们作为药物的使用和用于制造药物以治疗温血动物（如人类）中具有显著血管生成或血管成分的疾病，如固体肿瘤的治疗。本发明还涉及抑制a5b1并且对其他整合素具有适当选择性特征的化合物。
• NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：Yoshida Tomohiro

  公开号：US20100228026A1

  公开（公告）日：2010-09-09

  The invention provides a sulfonyl malonamide derivative, or a pharmacologically acceptable salt thereof or a solvate thereof, that has therapeutic and/or preventive effect(s) on various diseases due to its agonist action at AT 2 receptor, and is useful as a pharmaceutical agent for the treatment and/or prevention of diseases involving the renin-angiotensin-aldosterone system (RAAS).

  该发明提供了一种磺酰基马隆酰胺衍生物，或其药理学上可接受的盐或溶剂，由于其在AT2受体上的激动剂作用，对各种疾病具有治疗和/或预防作用，并且作为用于治疗和/或预防涉及肾素-血管紧张素-醛固酮系统（RAAS）疾病的药物剂形具有用处。
• L-Phenylalanine Derivatives
  申请人：Barry Simon Thomas

  公开号：US20090137601A1

  公开（公告）日：2009-05-28

  The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及抑制a5b1功能的化合物，其制备过程，以及包含其作为活性成分的制药组合物，以及它们作为药物在温血动物（如人类）中治疗具有显著血管生成或血管成分的疾病，如实体肿瘤的制剂中的用途。本发明还涉及抑制a5b1的化合物，以及对其他整合素具有适当选择性谱的化合物。
• CHEMICAL COMPOUNDS
  申请人：Arnould Jean Claude

  公开号：US20090203663A1

  公开（公告）日：2009-08-13

  The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及抑制a5b1功能的化合物，其制备过程，含有它们作为活性成分的制药组合物，它们作为药物的使用以及它们在制造用于治疗具有显著血管生成或血管成分的疾病的药物中的使用，如用于治疗实体肿瘤等温血动物（如人类）。本发明还涉及抑制a5b1的化合物，以及对其他整合素具有适当选择性特征的化合物。